![2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide structure, CAS 163451-81-8](https://www.2abiotech.com/storage/file/20260617/68e2685dc13a5406ec3cf95c43670f7a484095be.png)
CAS Number163451-81-8
Synonyms(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide; Aubagio; (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide; (Z)-2-Cyano-3-hydroxy-but-2-enoic acid (4-trifluoromethyl-phenyl)-amide; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; Teriflunomide; (Z)-2-Cyano-a',a',a'-trifluoro-3-hydroxy-p-crotonotoluidide; A771726
Molecular FormulaC12H9F3N2O2
Molecular Weight270.21
Purity≥98 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point410.8±45.0 °C at 760 mmHg
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 163451-81-8 |
| Catalog No. | 2A-1174190 |
| Chinese Name | 特立氟胺 |
| Synonyms | (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide; Aubagio; (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide; (Z)-2-Cyano-3-hydroxy-but-2-enoic acid (4-trifluoromethyl-phenyl)-amide; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; Teriflunomide; (Z)-2-Cyano-a',a',a'-trifluoro-3-hydroxy-p-crotonotoluidide; A771726 |
| Molecular Formula | C12H9F3N2O2 |
| Molecular Weight | 270.21 |
| Purity | ≥98 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 410.8±45.0 °C at 760 mmHg |
| Appearance | powder |
| Storage Condition | -20°C |
| Application | Teriflunomide is the active metabolite of leflunomide and is a drug used to treat rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore effectively reduces T cell and B cell proliferati |
| HTC | 2942000000 |
| PubChem ID | 605680 |
| InChI | 1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7- |
| InChI Key | UTNUDOFZCWSZMS-YFHOEESVSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| MSDS | msds/174530_1_163451_81_8.pdf |
| Bioactivity | Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology In Vitro Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS. Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes[1]. In Vivo Teriflunomide has demonstrated beneficial effects in two independent animal models of demyelinating disease. In the dark agouti rat model of experimental autoimmune encephalitis (EAE), teriflunomide administration results in clinical, histopathological, and electrophysiological evidence of efficacy both as a prophylactic and therapeutic agent. Similarly, in the female Lewis rat model of EAE, teriflunomide administration results in beneficial prophylactic and therapeutic clinical effects, with a delay in disease onset and symptom severity[1]. References [1]. Oh J, et al. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-90. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 410.8±45.0 °C at 760 mmHg Molecular Formula C12H9F3N2O2 Molecular Weight 270.207 Flash Point 202.3±28.7 °C Exact Mass 270.061615 PSA 73.12000 LogP 2.51 Vapour Pressure 0.0±1.0 mmHg at 25°C Index of Refraction 1.552 Storage condition -20°C |
| Use of | Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation. Properties Name teriflunomide Synonym More Synonyms Teriflunomide Biological Activity Description Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology In Vitro Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS. Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes[1]. In Vivo Teriflunomide has demonstrated beneficial effects in two independent animal models of demyelinating disease. In the dark agouti rat model of experimental autoimmune encephalitis (EAE), teriflunomide administration results in clinical, histopathological, and electrophysiological evidence of efficacy both as a prophylactic and therapeutic agent. Similarly, in the female Lewis rat model of EAE, teriflunomide administration results in beneficial prophylactic and therapeutic clinical effects, with a delay in disease onset and symptom severity[1]. References [1]. Oh J, et al. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-90. Chemical & Physical Properties Molecular Formula C12H9F3N2O2 Exact Mass 270.061615 PSA 73.12000 Index of Refraction 1.552 |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in Functional Building Blocks | ||
|---|---|---|
| 6-(TrifluoroMethyl)picoliniMidaMide hydrochloride | 264884-49-3 | 2A-1174073 |
| Methyl2-(2-amino-4-(trifluoromethyl)phenyl)acetate | 13544-08-6 | 2A-1174079 |
| 3-bromo-2-nitrobenzaldehyde | 882772-99-8 | 2A-1174120 |
| 6-(4-methylphenyl)sulfonyl-2-oxa-6-azaspiro[3.3]heptane | 13573-28-9 | 2A-1174177 |
| 6-(TRIFLUOROMETHYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE | 628332-15-0 | 2A-1174184 |
| 1-Bromo-3-chloromethyl-2-nitro-benzene | 1261583-24-7 | 2A-1174203 |
| 2-cyano-N-[4-(trifluoromethyl)phenyl]acetamide | 24522-30-3 | 2A-1174217 |
| 5-isothiocyanato-3-(trifluoromethyl)picolinonitrile | 951753-87-0 | 2A-1174255 |
| 4-(Bromomethyl)-3-cyanoBenzoic acid methyl ester | 219519-17-2 | 2A-1174271 |
| 2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile | 1231892-37-7 | 2A-1174278 |
| Browse all Functional Building Blocks products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS